| Identification | Back Directory | [Name]
ipsalazide | [CAS]
82101-17-5 | [Synonyms]
5-(Carboxymethylcarbamoyl-4-phenylazo)salicylic acid (disodium)
5-[[4-[(Sodiooxycarbonylmethyl)carbamoyl]phenyl]azo]-2-hydroxybenzoic acid sodium salt
Benzoic acid, 5-((4-(((carboxymethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt | [MDL Number]
MFCD31382377 | [MOL File]
82101-17-5.mol |
| Hazard Information | Back Directory | [Uses]
Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. | [in vivo]
No deaths or visible abnormalities occurrs within 7 days of a single oral dose of ipsalazide (4 g/kg in mice or 2 g/kg in rats). No abnormalities were seen at postmortem. The ipsalazide carrier molecule (ABG) is readily absorbed, with nearly half of the dose appearing in the urine. However, around 40% of the ABG was not recovered, and it is possible that this has undergone further metabolism, with loss of the aromatic amine function which is the basis for the colorimetric measurement of ABG[1]. | [References]
[1] Chan RP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15. DOI:10.1007/BF01299921 |
|
|